Linagliptin

Linagliptin
	File:Linagliptin.png
Systematic (IUPAC) name
	8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Clinical data
Routes of; administration	Oral
Legal status
Legal status	Investigational;
Identifiers
CAS Number	668270-12-0
ATC code	none
PubChem	CID 10096344
Chemical data
Formula	C25H26N8O2
Molar mass	472.54 g/mol[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Linagliptin (BI-1356, expected trade name Ondero) is a DPP-4 inhibitor developed by Boehringer Ingelheim undergoing research for type II diabetes.

Results from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.^[1]

References

H. Spreitzer (September 1, 2008). "Neue Wirkstoffe - BI-1356". Österreichische Apothekerzeitung (in German) (18/2008): 918.
Wang, Y, Serradell, N, Rosa, E, Castaner, R (2008). "BI-1356". Drugs of the Future. 33 (6): 473–477. doi:10.1358/dof.2008.033.06.1215244.

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

45px	This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. v d e